within Pharmacolibrary.Drugs.ATC.S;

model S01GX11
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 0.25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01GX11</td></tr><td>route:</td><td>ophthalmic</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Alcaftadine is an H1 histamine receptor antagonist used as a topical ophthalmic solution for the prevention of itching associated with allergic conjunctivitis. It is currently approved and marketed for this use.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for topical ocular administration in adults. No human systemic pharmacokinetic studies published; data primarily from product labeling and pharmacology reviews.</p><h4>References</h4><ol><li><p>Chigbu, DI, &amp; Coyne, AM (2015). Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis. <i>Clinical ophthalmology (Auckland, N.Z.)</i> 9 1215–1225. DOI:<a href=\"https://doi.org/10.2147/OPTH.S63790\">10.2147/OPTH.S63790</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26185412/\">https://pubmed.ncbi.nlm.nih.gov/26185412</a></p></li><li><p>Namdar, R, &amp; Valdez, C (2011). Alcaftadine: a topical antihistamine for use in allergic conjunctivitis. <i>Drugs of today (Barcelona, Spain : 1998)</i> 47(12) 883–890. DOI:<a href=\"https://doi.org/10.1358/dot.2011.47.12.1709243\">10.1358/dot.2011.47.12.1709243</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22348913/\">https://pubmed.ncbi.nlm.nih.gov/22348913</a></p></li><li><p>Bohets, H, et al., &amp; Shapiro, A (2011). Clinical pharmacology of alcaftadine, a novel antihistamine for the prevention of allergic conjunctivitis. <i>Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics</i> 27(2) 187–195. DOI:<a href=\"https://doi.org/10.1089/jop.2010.0153\">10.1089/jop.2010.0153</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21314437/\">https://pubmed.ncbi.nlm.nih.gov/21314437</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01GX11;
